Rexulti, Advertising Profile, See Their Ad Spend!
Por um escritor misterioso
Descrição
Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole - Kikuchi - 2021 - Neuropsychopharmacology Reports - Wiley Online Library
FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease
REXULTI- brexpiprazole tablet
FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients
PM360 2021 Trailblazer Awards Co-Promote or Partnership Initiative Gold Winner Otsuka, Lundbeck, and The Bloc
Otsuka, Lundbeck's sNDA for Rexulti received US FDA approval
Digital Ads Benchmark Report By Tinuiti, Q2 2023
Pre Mid-Terms: Political Ads Capture Attention
Pharmaceutical payments to psychiatrists and betrayal of the public good
Pharmacological and clinical profile of repurposed medications for MDD.
REXULTI TV Spot, 'These Days: Savings Card Benefits'
de
por adulto (o preço varia de acordo com o tamanho do grupo)
